|Bid||22.24 x 900|
|Ask||23.27 x 800|
|Day's Range||22.18 - 23.00|
|52 Week Range||13.92 - 28.18|
|Beta (5Y Monthly)||1.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 02, 2023 - Aug 07, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.33|
Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test.
Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE® SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha (FRα) to its Precise™ Oncology Solutions portfolio. The new biomarker adds another companion diagnostic option for providers to help guide treatment decisions for patients with ovarian cancer. FRα i
Investing.com -- Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: an Outperform initiation at Zions Bancorp and upgrades at KeyCorp, Greenhill, and Myriad Genetics.
Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.
SALT LAKE CITY, May 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has achieved the Great Place to Work® certification for 2023. The certification is based solely on what current employees say about their experience working at Myriad. This year, 86% of Myriad employees said the company is a great place to work – 29 percentage points higher than a typical U.S. company. “At Myriad Genetics we are committed
Myriad Genetics ( NASDAQ:MYGN ) First Quarter 2023 Results Key Financial Results Revenue: US$181.2m (up 9.9% from 1Q...
Myriad Genetics (MYGN) delivers a year-over-year increase in first-quarter revenues, reflecting a positive volume improvement across the portfolio.
Q1 2023 Myriad Genetics Inc Earnings Call
Myriad (MYGN) delivered earnings and revenue surprises of -10.53% and 5.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Highlights: First quarter testing volumes grew 21% year-over-year and 10% sequentially, excluding contributions from the SneakPeek® Early Gender DNA Test.In the first quarter: Hereditary cancer test volumes grew 24% year-over-year, the second consecutive quarter of double-digit growth year-over-year.Hereditary cancer test volumes in Women's Health grew 32% year-over-year.GeneSight® pharmacogenomics test volumes grew 31% year-over-year and 15% sequentially from the previous quarter.Prenatal test
SALT LAKE CITY, May 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will be participating in the upcoming BofA Securities Healthcare Conference in Las Vegas, NV. Myriad management will participate in a fireside chat on Tuesday, May 9 at 3:00 p.m. PT. A live and archived webcast of the presentation can be viewed in the investor relations section of Myriad’s website at www.myriad.com. About Myriad GeneticsMy
SALT LAKE CITY, April 26, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Wednesday May 3, 2023 at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the period ending March 31, 2023. Conference Call and
Myriad Genetics (MYGN) and Intermountain Precision Genomics receive the New York State Clinical Laboratory Permit to offer solid tumor testing to patients in all 50 U.S. states.
Medication failure leads 45% of respondents with depression and/or anxiety to turn to unhealthy coping mechanisms Respondents may view these behaviors as addictive or unhealthy coping mechanisms, yet many still use them Respondents may view these behaviors as addictive or unhealthy coping mechanisms, yet many still use them Left to right: Depression rates increase from 2022 to 2023 & Anxiety rates increase from 2022 to 2023 Left to right: Depression rates increase from 2022 to 2023 & Anxiety rat
Intermountain Precision Genomics Laboratory receives certification from NYS Department of Health Clinical Laboratory Evaluation ProgramSALT LAKE CITY, April 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, a service of Intermountain Health, are now certified to offer solid tumor testing to patients in all 50 U.S. states after receiving the New York State Clinical Laboratory Permit. This a
Myriad Genetics' (MYGN) latest program will increase access to affordable genetic testing. It will also aid in identifying and elevating high-risk patient care.
New program will increase access to affordable genetic testing while also helping to identify and elevate high-risk patient careSALT LAKE CITY, April 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and SimonMed® Imaging, one of the largest independent outpatient medical imaging providers and physician radiology practices in the United States, today announced the planned launch of a new hereditary cancer assessment program th
Myriad Genetics (MYGN), together with Illumina, will seek joint HRD companion diagnostics partnerships with pharmaceutical companies globally.
Key Insights Using the 2 Stage Free Cash Flow to Equity, Myriad Genetics fair value estimate is US$19.13 With US$22.90...
Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industrySALT LAKE CITY, March 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetic, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the expansion of a strategic partnership to broaden access to and availability of oncology homologous rec
Myriad Genetics (MYGN) hereditary cancer testing volume registered strong growth in the fourth quarter. GeneSight comes up with yet another strong performance.
Q4 2022 Myriad Genetics Inc Earnings Call
SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the first evidence-based expanded carrier screening (ECS) practice guidelines for reproductive risk assessment published by the National Society of Genetic Counselors (NSGC) in the Journal of Genetic Counseling. NSGC’s guidelines support equitable access and care to all patients looking to start or grow their families by rec
Myriad (MYGN) delivered earnings and revenue surprises of 25% and 5.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Highlights: Fourth quarter testing volumes grew 26% year-over-year, and 11% year-over-year excluding the contribution from the recent acquisition of Gateway Genomics and its SneakPeek® Early Gender DNA Test. GeneSight, the company's pharmacogenomics test, grew revenue 36% for the full year 2022.Gross margin for the fourth quarter was approximately 70% reflecting underlying price stability and disciplined cost management.Diluted GAAP earnings per share (EPS) were $(0.52) and adjusted EPS were $(0